Anavex Life Sciences announced the appointment of Kun Jin, Ph.D., as Vice President, Head of Biostatistics. Jin will draw on his extensive experience, including recently as the Statistical Team Leader at the U.S. Food and Drug Administration.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AVXL:
- Anavex price target lowered to $28 from $35 at BTIG
- Anavex reports Q1 EPS (17c), consensus (19c)
- Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
- Anavex could submit blarcamesine to FDA by year end, says H.C. Wainwright
- Anavex announces exceeding enrollment target for ANAVEX2-73 EXCELLENCE trial
